<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-PHTWTXL4</identifier><date>2015</date><creator>Obreza, Aleš</creator><relation>documents/doc/P/URN_NBN_SI_doc-PHTWTXL4_001.pdf</relation><relation>documents/doc/P/URN_NBN_SI_doc-PHTWTXL4_001.txt</relation><format format_type="issue">2</format><format format_type="volume">66</format><format format_type="type">article</format><format format_type="extent">str. 209-214</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID">3859313</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-PHTWTXL4</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">antiandogeni</subject><subject language_type_id="slv">antiholinergiki</subject><subject language_type_id="slv">gonadoliberinski receptorji</subject><subject language_type_id="slv">mirabegron</subject><subject language_type_id="slv">prekomerna aktivnost sečnega mehurja</subject><subject language_type_id="slv">prostata</subject><subject language_type_id="eng">prostate</subject><subject language_type_id="slv">rak (medicina)</subject><subject language_type_id="slv">taksani</subject><title>Drugs for treating diseases of prostate and bladder</title><title>Zdravila za zdravljenje bolezni prostate in mehurja</title></Record>